OncoMed Pharmaceuticals Initiates Randomized Phase 2 "ALPINE" Clinical Trial Of Tarextumab (Anti-Notch 2/3, OMP-59R5) For Pancreatic Cancer

By: via Benzinga
OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.